Linical CoTSE:2183 +2.50%49 Quick Ratio is 1.31 as of Mar. 2026, which is 26% below its 10-year median of 1.78. GuruFocus rates TSE:2183 with a GF Score™ of 49/100 and a GF Value™ of 円310.47 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,412 Biotechnology companies, Linical Co ranks worse than 75.85% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Linical Co's quick ratio for the quarter that ended in Mar. 2026 was 1.31.
Linical Co has a quick ratio of 1.31. It generally indicates good short-term financial strength.
The historical rank and industry rank for Linical Co's Quick Ratio or its related term are showing as below:
TSE:2183'
s Quick Ratio Range Over the Past 10 Years
Min: 1.31 Med: 1.78 Max: 2.54
Current: 1.31
During the past 13 years, Linical Co's highest Quick Ratio was 2.54. The lowest was 1.31. And the median was 1.78.
TSE:2183's Quick Ratio is ranked worse than 75.85% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TSE:2183: 1.31
Linical Co (TSE:2183) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Linical Co Quick Ratio Related Terms
Linical Co Quick Ratio Historical Data
* Premium members only.
The historical data trend for Linical Co's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2183 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Linical Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Linical Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Linical Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Linical Co's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Linical Co's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Linical Co (TSE:2183) has a Quick Ratio of 1.31 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Linical Co and its competitors. This is 26% below median its historical median of 1.78. Over the past decade, Linical Co's Quick Ratio has ranged from 1.31 to 2.54. According to the industry distribution chart, Linical Co ranks #1071 out of 1412 companies in the Biotechnology industry, placing it in the top 75.8%.
Is Linical Co's Quick Ratio too high?
Linical Co's current Quick Ratio of 1.31 is 26% below median its 10-year median of 1.78. Over the past 10 years, this metric has ranged from a low of 1.31 to a high of 2.54. The Biotechnology industry median Quick Ratio is 3.60. Linical Co's value of 1.31 is 63.6% below this industry median. Based on the distribution chart, Linical Co ranks #1071 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Linical Co has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Linical Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Linical Co ranks #1071 out of 1412 companies for Quick Ratio. This places Linical Co in the lower half of its industry. The industry median Quick Ratio is 3.60. Linical Co's value of 1.31 is 63.6% below this benchmark. Historically, Linical Co's own Quick Ratio has ranged from 1.31 to 2.54 over the past decade. While the company's 10-year median is 1.78 vs. the industry median of 3.60, Linical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Linical Co's current Quick Ratio of 1.31 is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Linical Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Linical Co's current Quick Ratio is 1.31, which is 26% below median its own 10-year median of 1.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Linical Co stock overvalued right now?
Based on GuruFocus' analysis, Linical Co (TSE:2183) is currently considered Possible Value Trap. The stock's GF Value™ is 円310.47, compared to a current price of 円205.00 — trading 34% below its estimated fair value. The current Quick Ratio is 1.31, which is 26% below median its 10-year median of 1.78 and 63.6% below the Biotechnology industry median of 3.60. Linical Co's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Linical Co (TSE:2183), the current Quick Ratio is 1.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Linical Co (TSE:2183) Overvalued in 2026?
Based on GuruFocus' analysis, Linical Co stock appears to be undervalued.
The current stock price of 円205.00 is trading 34% below its estimated GF Value™ of 円310.47.
GuruFocus considers Linical Co to be Possible Value Trap.
Key valuation signals for TSE:2183:
Quick Ratio: 1.31 (26% below median its 10-year median of 1.78)
GF Value™: 円310.47 vs. price of 円205.00 (34% below fair value)
Industry Position: 63.6% below the Biotechnology median (#1071 of 1412)
No single metric tells the full story. See the TSE:2183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2183 has been successfully added to your 
